SNORD32B: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD32B

NCBI ID: G692092

SNORD32B

Other Name(s): Small nucleolar RNA, C/D box 32B | U32B | small nucleolar RNA, C/D box 32B

SNORD32B: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a class of non-coding RNA molecules that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the most well-known snRNAs is SNORD32B, which is located in the C/D box region on chromosome 8 and is expressed in a variety of tissues and cell types.

SNORD32B is a 24.1 kilobase (kb) RNA molecule that consists of 1,944 unique amino acid residues. It is primarily expressed in the nuclei of eukaryotic cells and is involved in the regulation of various cellular processes, including DNA replication, transcription, and translation.

One of the unique features of SNORD32B is its structure. It has a highly conserved core, which is composed of a series of alternating double-stranded regions, as well as a variable region that includes a unique G-Crich sequence and several putative RNA binding sites. The variable region of SNORD32B is known to play a role in its protein-coding potential and has been implicated in the regulation of various cellular processes.

SNORD32B has also been shown to have several potential drug targets. One of the most promising targets is the protein encoded by the SNORD32B gene, which is known as snORD32B-containing RNA-binding protein (SBP). The SAPB protein is a 21.8 kDa protein that is expressed in various tissues and cell types and is involved in the regulation of cellular processes, including cell adhesion, migration, and the association with the microtubules of cells.

SBP is a protein that can interact with SNORD32B and enhance its stability in the nucleus. This interaction between SNORD32B and SAPB has led to the idea that SNORD32B may be a drug target for diseases that are characterized by the over-expression or dysfunction of SAPB.

Another potential drug target for SNORD32B is the interaction between SNORD32B and the protein encoded by the KLF1 gene. KLF1 is a non-coding RNA molecule that is expressed in various tissues and cell types and is involved in the regulation of gene expression. Research shows that, the SNORD32B-KLF1 interaction is involved in the regulation of cellular processes, including cell growth, apoptosis, and translation.

SNORD32B has also been shown to interact with the protein encoded by the CDK2 gene, which is a transcription factor that is involved in the regulation of gene expression. This interaction between SNORD32B and CDK2 has led to the idea that SNORD32B may be a drug target for diseases that are characterized by the over-expression or dysfunction of CDK2.

In conclusion, SNORD32B is a small nucleolar RNA molecule that is expressed in various tissues and cell types and is involved in the regulation of various cellular processes. Its unique structure and the interaction with protein coding genes make it a promising drug target for diseases characterized by the over-expression or dysfunction of SAPB, KLF1, and CDK2. Further research is needed to fully understand the role of SNORD32B in disease and to develop effective treatments.

Protein Name: Small Nucleolar RNA, C/D Box 32B

The "SNORD32B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD32B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets